427 related articles for article (PubMed ID: 26094596)
1. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.
Ambrosi G; Ghezzi C; Zangaglia R; Levandis G; Pacchetti C; Blandini F
Neurobiol Dis; 2015 Oct; 82():235-242. PubMed ID: 26094596
[TBL] [Abstract][Full Text] [Related]
2. Deficiency of Glucocerebrosidase Activity beyond Gaucher Disease: PSAP and LIMP-2 Dysfunctions.
Pavan E; Peruzzo P; Cattarossi S; Bergamin N; Bordugo A; Sechi A; Scarpa M; Biasizzo J; Colucci F; Dardis A
Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928321
[TBL] [Abstract][Full Text] [Related]
3. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
McNeill A; Magalhaes J; Shen C; Chau KY; Hughes D; Mehta A; Foltynie T; Cooper JM; Abramov AY; Gegg M; Schapira AH
Brain; 2014 May; 137(Pt 5):1481-95. PubMed ID: 24574503
[TBL] [Abstract][Full Text] [Related]
4. Ambroxol reverses tau and α-synuclein accumulation in a cholinergic N370S GBA1 mutation model.
Yang SY; Taanman JW; Gegg M; Schapira AHV
Hum Mol Genet; 2022 Jul; 31(14):2396-2405. PubMed ID: 35179198
[TBL] [Abstract][Full Text] [Related]
5. Glucocerebrosidase enzyme activity in GBA mutation Parkinson's disease.
Ortega RA; Torres PA; Swan M; Nichols W; Boschung S; Raymond D; Barrett MJ; Johannes BA; Severt L; Shanker V; Hunt AL; Bressman S; Pastores GM; Saunders-Pullman R
J Clin Neurosci; 2016 Jun; 28():185-6. PubMed ID: 26857292
[TBL] [Abstract][Full Text] [Related]
6. Glucocerebrosidase activity, cathepsin D and monomeric α-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation.
Yang SY; Gegg M; Chau D; Schapira A
Neurobiol Dis; 2020 Feb; 134():104620. PubMed ID: 31634558
[TBL] [Abstract][Full Text] [Related]
7. Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons.
Magalhaes J; Gegg ME; Migdalska-Richards A; Schapira AH
Sci Rep; 2018 Jan; 8(1):1385. PubMed ID: 29362387
[TBL] [Abstract][Full Text] [Related]
8. The relationship between glucocerebrosidase mutations and Parkinson disease.
Migdalska-Richards A; Schapira AH
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
[TBL] [Abstract][Full Text] [Related]
9. Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Mullin S; Smith L; Lee K; D'Souza G; Woodgate P; Elflein J; Hällqvist J; Toffoli M; Streeter A; Hosking J; Heywood WE; Khengar R; Campbell P; Hehir J; Cable S; Mills K; Zetterberg H; Limousin P; Libri V; Foltynie T; Schapira AHV
JAMA Neurol; 2020 Apr; 77(4):427-434. PubMed ID: 31930374
[TBL] [Abstract][Full Text] [Related]
10. Lysosomal ceramides regulate cathepsin B-mediated processing of saposin C and glucocerebrosidase activity.
Kim MJ; Jeong H; Krainc D
Hum Mol Genet; 2022 Jul; 31(14):2424-2437. PubMed ID: 35181782
[TBL] [Abstract][Full Text] [Related]
11. A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson's disease.
Burbulla LF; Jeon S; Zheng J; Song P; Silverman RB; Krainc D
Sci Transl Med; 2019 Oct; 11(514):. PubMed ID: 31619543
[TBL] [Abstract][Full Text] [Related]
12. A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers.
Yang SY; Beavan M; Chau KY; Taanman JW; Schapira AHV
Stem Cell Reports; 2017 Mar; 8(3):728-742. PubMed ID: 28216145
[TBL] [Abstract][Full Text] [Related]
13. Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism.
Kopytova AE; Rychkov GN; Nikolaev MA; Baydakova GV; Cheblokov AA; Senkevich KA; Bogdanova DA; Bolshakova OI; Miliukhina IV; Bezrukikh VA; Salogub GN; Sarantseva SV; Usenko TC; Zakharova EY; Emelyanov AK; Pchelina SN
Parkinsonism Relat Disord; 2021 Mar; 84():112-121. PubMed ID: 33609962
[TBL] [Abstract][Full Text] [Related]
14. Saposin C protects glucocerebrosidase against α-synuclein inhibition.
Yap TL; Gruschus JM; Velayati A; Sidransky E; Lee JC
Biochemistry; 2013 Oct; 52(41):7161-3. PubMed ID: 24070323
[TBL] [Abstract][Full Text] [Related]
15. Fibroblasts from idiopathic Parkinson's disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2.
Thomas R; Moloney EB; Macbain ZK; Hallett PJ; Isacson O
Mol Brain; 2021 Jan; 14(1):16. PubMed ID: 33468204
[TBL] [Abstract][Full Text] [Related]
16. Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues.
Menozzi E; Toffoli M; Schapira AHV
Pharmacol Ther; 2023 Jun; 246():108419. PubMed ID: 37080432
[TBL] [Abstract][Full Text] [Related]
17. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase.
Bendikov-Bar I; Maor G; Filocamo M; Horowitz M
Blood Cells Mol Dis; 2013 Feb; 50(2):141-5. PubMed ID: 23158495
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cysteine protease cathepsin L increases the level and activity of lysosomal glucocerebrosidase.
Kim MJ; Kim S; Reinheckel T; Krainc D
JCI Insight; 2024 Feb; 9(3):. PubMed ID: 38329128
[TBL] [Abstract][Full Text] [Related]
19. Saposin C, Key Regulator in the Alpha-Synuclein Degradation Mediated by Lysosome.
Ruz C; Barrero FJ; Pelegrina J; Bandrés-Ciga S; Vives F; Duran R
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233303
[TBL] [Abstract][Full Text] [Related]
20. The Effect of p.G2019S Mutation in the
Usenko TS; Timofeeva A; Beletskaia M; Basharova K; Baydakova G; Bezrukova A; Grunina M; Emelyanov A; Miliukhina I; Zakharova E; Pchelina S
J Integr Neurosci; 2024 Jan; 23(1):16. PubMed ID: 38287861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
